解析大 B 细胞淋巴瘤 CAR-T 细胞治疗诊疗路径：法国全国性研究（2018-2023）的启示

This study describes the inpatient care pathway for 1914 Large B-cell Lymphoma (LBCL) patients treated with CAR T-cell therapy in France between 2018 and 2023 and identifies factors influencing their management. Based on a retrospective analysis of the French national hospital database, we found the average CAR T-cell infusion stay was shorter for patients in the second line of treatment versus later lines (20. 4 vs. 23. 8 days).

The specific product used was also influential; for example, lisocabtagene maraleucel was associated with shorter stays and fewer ICU admissions than axicabtagene ciloleucel. A multivariate analysis confirmed that while patient characteristics and the CAR T-cell product influenced outcomes, higher center experience was a primary determinant.

More experienced centers had shorter hospital stays and a higher probability of patients being discharged home, demonstrating that the management of CAR T-cell patients is largely dependent on institutional experience.